Back

Does the risk for heart failure (HF) modulate the effectiveness of empagliflozin on HF hospitalisation or CV death in patients with type 2 diabetes without HF? Insights from EMPA-REG OUTCOME

28 August 2017 (09:30 - 09:45)
Organised by:
Congress Presentation Part of: Late-Breaking Science in Heart Failure Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

5 More presentations in this session

Presentation thumbnail
Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study
Professor A. Norhammar (Stockholm, SE)
Slides Video
Presentation thumbnail
Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials
Professor D. Kotecha (Birmingham, GB)
Slides Video
Presentation thumbnail
Marked variation in the efficacy of beta-blockers across cardiovascular health: A Global systematic assessment of mortality, myocardial infarction and stroke
Doctor O. Ziff (Birmingham, GB)
Slides Video
Presentation thumbnail
Heart Failure-Wii study
Professor T. Jaarsma (Linkoping, SE)
Slides Video
Presentation thumbnail
Predicting right heart failure after implantation of continuous flow left ventricular assist devices (EUROMACS-RHF) score: analysis of the EUROMACS data
Professor O. Soliman (Dublin, IE)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science in Heart Failure

The Event

Event poster

ESC Congress 2017

28 August 2017 09:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources